ClinicalTrials.gg
CompletedNCT01096680Updated Jun 14, 2021Results posted

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

A Phase 2 interventional study of SPD489 20 mg and SPD489 50 mg in Sleep Deprivation, sponsored by Shire. Completed at 1 site in United States. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 146 studies in Sleep Deprivation with a site in United States — 30 open to participants now, 35 under way, none of them phase 3. Sleep Deprivation · United States.

Enrollment
24th of 127
135 · median 56
Started
2010
with 4 others
Phase 2
6 of 146
none open now
Registered
26th of 146
by date

Among the 146 studies in Sleep Deprivation with a site in United States, this one is the 24th largest by enrollment of the 127 interventional ones that give a count, is one of 5 that started in 2010, is one of 6 in phase 2, and was the 26th registered.

Sleep Deprivation

314 studies on the registry are indexed under Sleep Deprivation; 59 are open to participants now.

Browse Sleep Deprivation studies →

Open to participants now

30 of the 146 studies in Sleep Deprivation with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Sleep Deprivation studies recruiting now, 11 (26%) set no upper age limit and 28 (65%) stop at 75 or younger; 5 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Sleep Deprivation with a site in United States, or all of them as a file.
02

Study summary

This is a double-blind, single center, parallel group, placebo and active comparator, controlled study to characterize the wake promoting effects of single doses of SPD489 in healthy adult male undergoing acute sleep deprivation.

03

Conditions studied

  • Sleep Deprivation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects between the ages of 18-40 years.
  • The subject is in good health and must have a satisfactory medical assessment with no and relevant abnormalities (of medical history, physical examination, (ECG), clinical laboratory evaluation (hematology, biochemistry, and urinalysis).
  • Subject has a history of regular sleep-wake habits, routinely spending 6.5-8 hours in bed nightly, and does not oversleep by more than 3 hours on weekends.
  • Subject has the ability to provide written, signed, and dated (personally) to participate in the study, in accordance with the International Conference on Harmonisation Good Clinical Practice Guideline E6 and applicable regulations, before completing any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Current or relevant previous history of serious, severe, or unstable (acute or progressive) physical or psychiatric illness, any medical disorder that may require treatment or make this subject unlikely to fully complete the study, or any condition that presents undue risk from SPD489 or armodafinil or procedures. Comorbid psychiatric diagnosis will be established by a psychiatric evaluation that includes the Mini International Neuropsychiatric Interview (MINI)-Plus.
  • Subject is currently considered a suicide risk, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating suicidal ideation.
  • Subject has a known or suspected sleep disorder, or another disorder associated with excessive daytime sleepiness, or any other diagnosis that would interfere with assessing sleepiness in subjects with study related induced sleepiness or abnormal findings on the initial PSG conducted on Day -1 such as, but not limited to, Apnea-Hypopnea Index (AHI) or Periodic Limb Movement Arousal Index (PLMAI) >10.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    SPD489 20 mg

    Drug: SPD489 20 mg

  • Experimental
    SPD489 50 mg

    Drug: SPD489 50 mg

  • Experimental
    SPD489 70 mg

    Drug: SPD489 70 mg

  • Active comparator
    Armodafinil

    Drug: Armodafinil

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Single oral dose of 20 mg

    Also known as: Vyvanse

  • Single oral dose of 50 mg

    Also known as: Vyvanse

  • Single oral dose of 70 mg

    Also known as: Vyvanse

  • Single oral dose of 250 mg

  • DrugPlacebo

    Single oral dose

06

What researchers measure

Primary outcomes

  1. Maintenance of Wakefulness Test (MWT)

    The MWT was conducted to determine the subjects' ability to stay awake. Subjects sat in a darkened room and were told to "stay awake as long as possible" during the 30 minute session. This is an indicator of how well you are able to function and remain alert in quiet times of inactivity. Higher times are better.

    Time frame: Over a period of 8 hours

Secondary outcomes

  1. Karolinska Sleepiness Scale (KSS) Scores

    The KSS is a 9-point scale on which the subject rates sleepiness from 1 (very alert) to 9 (very sleepy/fighting sleep). Lower score is better.

    Time frame: Over a period of 15 hours

  2. KSS Scores by Timepoint

    The KSS is a 9-point scale on which the subject rates sleepiness from 1 (very alert) to 9 (very sleepy/fighting sleep). Lower score is better.

    Time frame: Over a period of 15 hours

  3. Psychomotor Vigilance Task (PVT) Scores

    PVT assesses behavioral alertness. Subjects were required to respond to a visual stimulus by pressing a button on a mechanical device and the reaction time was measured. Higher scores indicate attention lapses.

    Time frame: Over a period of 12 hours

  4. PVT Scores by Timepoint

    PVT assesses behavioral alertness. Subjects were required to respond to a visual stimulus by pressing a button on a mechanical device and the reaction time was measured. Higher scores indicate attention lapses.

    Time frame: Over a period of 12 hours

07

Results

Posted Jun 23, 2011

Participant flow

Participant flow — Overall Study
MilestoneSPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlacebo
Started2727272727
Completed2727272727
Not completed00000

Outcome measures

PrimaryMaintenance of Wakefulness Test (MWT)

The MWT was conducted to determine the subjects' ability to stay awake. Subjects sat in a darkened room and were told to "stay awake as long as possible" during the 30 minute session. This is an indicator of how well you are able to function and remain alert in quiet times of inactivity. Higher times are better.

Time frame:
Over a period of 8 hours
Reported as:
Least squares mean · Minutes
Maintenance of Wakefulness Test (MWT)
MinutesSPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlacebo
Maintenance of Wakefulness Test (MWT)23.3 ± 1.1027.9 ± 0.6429.3 ± 0.4427.6 ± 0.6315.3 ± 1.00
Statistical analysis
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 8.0 · 95% CI 5.0 to 10.9
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 12.6 · 95% CI 10.2 to 15.0
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 14.0 · 95% CI 11.7 to 16.2
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 12.3 · 95% CI 9.9 to 14.7
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0014 · Mean difference (final values): -4.3 · 95% CI -6.9 to -1.8
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.7601 · Mean difference (final values): 0.3 · 95% CI -1.5 to 2.1
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0351 · Mean difference (final values): 1.7 · 95% CI 0.1 to 3.2
SecondaryKarolinska Sleepiness Scale (KSS) Scores

The KSS is a 9-point scale on which the subject rates sleepiness from 1 (very alert) to 9 (very sleepy/fighting sleep). Lower score is better.

Time frame:
Over a period of 15 hours
Reported as:
Least squares mean · Units on a scale
Karolinska Sleepiness Scale (KSS) Scores
Units on a scaleSPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlacebo
Karolinska Sleepiness Scale (KSS) Scores4.7 ± 0.214.0 ± 0.213.6 ± 0.214.7 ± 0.215.2 ± 0.21
Statistical analysis
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.1123 · Mean difference (final values): -0.5 · 95% CI -1.1 to 0.1
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): -1.2 · 95% CI -1.8 to -0.6
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -1.6 · 95% CI -2.2 to -1.0
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.0947 · Mean difference (final values): -0.5 · 95% CI -1.1 to 0.1
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9393 · Mean difference (final values): 0.0 · 95% CI -0.6 to 0.6
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0297 · Mean difference (final values): -0.7 · 95% CI -1.3 to -0.1
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0004 · Mean difference (final values): -1.1 · 95% CI -1.7 to -0.5
SecondaryKSS Scores by Timepoint

The KSS is a 9-point scale on which the subject rates sleepiness from 1 (very alert) to 9 (very sleepy/fighting sleep). Lower score is better.

Time frame:
Over a period of 15 hours
Reported as:
Least squares mean · Units on a scale
KSS Scores by Timepoint
Units on a scaleSPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlacebo
7:50pm2.9 ± 0.193.0 ± 0.192.6 ± 0.192.6 ± 0.192.8 ± 0.19
8:50pm2.7 ± 0.202.7 ± 0.202.6 ± 0.202.7 ± 0.203.0 ± 0.20
9:50pm2.9 ± 0.233.1 ± 0.232.6 ± 0.233.1 ± 0.233.1 ± 0.23
10:50pm2.8 ± 0.263.2 ± 0.262.4 ± 0.272.9 ± 0.263.7 ± 0.27
11:50pm3.2 ± 0.293.1 ± 0.292.5 ± 0.293.4 ± 0.293.9 ± 0.29
12:50am3.6 ± 0.292.9 ± 0.292.6 ± 0.293.3 ± 0.294.5 ± 0.29
1:50am4.0 ± 0.313.2 ± 0.313.0 ± 0.313.8 ± 0.314.7 ± 0.31
2:50am4.5 ± 0.353.7 ± 0.353.5 ± 0.354.7 ± 0.355.7 ± 0.35
3:50am5.2 ± 0.363.9 ± 0.363.7 ± 0.365.5 ± 0.366.4 ± 0.36
4:50am6.1 ± 0.364.4 ± 0.364.2 ± 0.366.0 ± 0.366.6 ± 0.36
5:50am6.7 ± 0.375.1 ± 0.374.6 ± 0.376.3 ± 0.377.1 ± 0.37
6:50am6.7 ± 0.385.7 ± 0.384.8 ± 0.386.7 ± 0.387.3 ± 0.38
7:50am6.5 ± 0.395.5 ± 0.394.7 ± 0.396.6 ± 0.397.2 ± 0.39
8:50am5.9 ± 0.415.0 ± 0.414.4 ± 0.416.0 ± 0.415.4 ± 0.41
9:50am5.6 ± 0.384.6 ± 0.384.5 ± 0.385.7 ± 0.385.9 ± 0.38
10:50am6.2 ± 0.415.4 ± 0.415.0 ± 0.416.0 ± 0.416.2 ± 0.41
Statistical analysis
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.7758 · Mean difference (final values): 0.1 · 95% CI -0.5 to 0.6
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.1798 · Mean difference (final values): 0.4 · 95% CI -0.2 to 0.9
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.6090 · Mean difference (final values): 0.1 · 95% CI -0.4 to 0.7
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.1169 · Mean difference (final values): 0.4 · 95% CI -0.1 to 1.0
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.3028 · Mean difference (final values): -0.3 · 95% CI -0.8 to 0.3
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9831 · Mean difference (final values): 0.0 · 95% CI -0.5 to 0.5
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.2887 · Mean difference (final values): -0.3 · 95% CI -0.8 to 0.2
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.4395 · Mean difference (final values): -0.2 · 95% CI -0.8 to 0.3
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9019 · Mean difference (final values): 0.0 · 95% CI -0.5 to 0.6
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.3419 · Mean difference (final values): -0.3 · 95% CI -0.8 to 0.3
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9581 · Mean difference (final values): 0.0 · 95% CI -0.6 to 0.5
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.2572 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.2
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.8085 · Mean difference (final values): -0.1 · 95% CI -0.6 to 0.5
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.3678 · Mean difference (final values): -0.3 · 95% CI -0.8 to 0.3
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.3732 · Mean difference (final values): -0.3 · 95% CI -0.9 to 0.4
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.4924 · Mean difference (final values): -0.2 · 95% CI -0.9 to 0.4
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.9798 · Mean difference (final values): 0.0 · 95% CI -0.7 to 0.6
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.8557 · Mean difference (final values): 0.1 · 95% CI -0.6 to 0.7
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.0998 · Mean difference (final values): -0.5 · 95% CI -1.2 to 0.1
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.1479 · Mean difference (final values): -0.5 · 95% CI -1.1 to 0.2
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.8358 · Mean difference (final values): -0.1 · 95% CI -0.7 to 0.6
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.0199 · Mean difference (final values): -0.9 · 95% CI -1.6 to -0.1
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.7625 · Mean difference (final values): -0.1 · 95% CI -0.9 to 0.6
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.1936 · Mean difference (final values): -0.5 · 95% CI -1.2 to 0.3
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.4534 · Mean difference (final values): 0.3 · 95% CI -0.5 to 1.0
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.0012 · Mean difference (final values): -1.2 · 95% CI -2.0 to -0.5
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.2072 · Mean difference (final values): -0.5 · 95% CI -1.2 to 0.3
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.0413 · Mean difference (final values): -0.8 · 95% CI -1.5 to 0.0
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.1086 · Mean difference (final values): -0.7 · 95% CI -1.5 to 0.1
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.5843 · Mean difference (final values): -0.2 · 95% CI -1.0 to 0.6
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0571 · Mean difference (final values): -0.8 · 95% CI -1.6 to 0.0
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.3965 · Mean difference (final values): -0.3 · 95% CI -1.2 to 0.5
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.0009 · Mean difference (final values): -1.4 · 95% CI -2.2 to -0.6
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0211 · Mean difference (final values): -1.0 · 95% CI -1.8 to -0.1
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.2863 · Mean difference (final values): -0.4 · 95% CI -1.2 to 0.4
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.0428 · Mean difference (final values): -0.8 · 95% CI -1.7 to 0.0
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.3757 · Mean difference (final values): 0.4 · 95% CI -0.5 to 1.2
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): -1.6 · 95% CI -2.4 to -0.8
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.3535 · Mean difference (final values): -0.4 · 95% CI -1.2 to 0.4
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -1.9 · 95% CI -2.7 to -1.1
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.1131 · Mean difference (final values): -0.7 · 95% CI -1.5 to 0.2
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.0039 · Mean difference (final values): -1.2 · 95% CI -2.0 to -0.4
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.1302 · Mean difference (final values): -0.7 · 95% CI -1.5 to 0.2
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.6138 · Mean difference (final values): 0.2 · 95% CI -0.6 to 1.1
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0008 · Mean difference (final values): -1.5 · 95% CI -2.3 to -0.6
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.1643 · Mean difference (final values): -0.6 · 95% CI -1.5 to 0.3
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): -1.7 · 95% CI -2.5 to -0.8
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0782 · Mean difference (final values): -0.8 · 95% CI -1.6 to 0.1
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.0441 · Mean difference (final values): -0.9 · 95% CI -1.7 to 0.0
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.0193 · Mean difference (final values): -1.2 · 95% CI -2.2 to -0.2
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.7071 · Mean difference (final values): -0.2 · 95% CI -1.2 to 0.8
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): -1.9 · 95% CI -2.9 to -0.9
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0611 · Mean difference (final values): -0.9 · 95% CI -1.9 to 0.0
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -2.2 · 95% CI -3.2 to -1.2
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0160 · Mean difference (final values): -1.2 · 95% CI -2.2 to -0.2
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.0480 · Mean difference (final values): -1.0 · 95% CI -2.0 to 0.0
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.0234 · Mean difference (final values): -1.2 · 95% CI -2.2 to -0.2
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.5624 · Mean difference (final values): -0.3 · 95% CI -1.3 to 0.7
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -2.5 · 95% CI -3.5 to -1.5
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0022 · Mean difference (final values): -1.6 · 95% CI -2.6 to -0.6
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -2.7 · 95% CI -3.7 to -1.6
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0008 · Mean difference (final values): -1.8 · 95% CI -2.8 to -0.8
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.0883 · Mean difference (final values): -0.9 · 95% CI -1.9 to 0.1
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.3093 · Mean difference (final values): -0.5 · 95% CI -1.5 to 0.5
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.8871 · Mean difference (final values): 0.1 · 95% CI -0.9 to 1.1
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -2.2 · 95% CI -3.2 to -1.2
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0022 · Mean difference (final values): -1.6 · 95% CI -2.6 to -0.6
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -2.4 · 95% CI -3.4 to -1.4
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0006 · Mean difference (final values): -1.8 · 95% CI -2.8 to -0.8
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.2462 · Mean difference (final values): -0.6 · 95% CI -1.6 to 0.4
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.4427 · Mean difference (final values): -0.4 · 95% CI -1.4 to 0.6
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.4405 · Mean difference (final values): 0.4 · 95% CI -0.6 to 1.4
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0003 · Mean difference (final values): -2.0 · 95% CI -3.0 to -0.9
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0279 · Mean difference (final values): -1.2 · 95% CI -2.2 to -0.1
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -2.5 · 95% CI -3.5 to -1.5
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0015 · Mean difference (final values): -1.7 · 95% CI -2.7 to -0.7
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.1246 · Mean difference (final values): -0.8 · 95% CI -1.8 to 0.2
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.3067 · Mean difference (final values): -0.6 · 95% CI -1.6 to 0.5
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.8940 · Mean difference (final values): 0.1 · 95% CI -1.0 to 1.1
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0034 · Mean difference (final values): -1.6 · 95% CI -2.7 to -0.5
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0708 · Mean difference (final values): -1.0 · 95% CI -2.0 to 0.1
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -2.5 · 95% CI -3.6 to -1.4
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0006 · Mean difference (final values): -1.9 · 95% CI -2.9 to -0.8
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.2476 · Mean difference (final values): -0.6 · 95% CI -1.7 to 0.4
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.2310 · Mean difference (final values): -0.7 · 95% CI -1.8 to 0.4
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.8369 · Mean difference (final values): -0.1 · 95% CI -1.2 to 1.0
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0035 · Mean difference (final values): -1.6 · 95% CI -2.7 to -0.5
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0498 · Mean difference (final values): -1.1 · 95% CI -2.2 to 0.0
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -2.5 · 95% CI -3.6 to -1.4
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0007 · Mean difference (final values): -1.9 · 95% CI -3.0 to -0.8
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.3198 · Mean difference (final values): -0.5 · 95% CI -1.6 to 0.5
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.3750 · Mean difference (final values): 0.5 · 95% CI -0.6 to 1.7
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.7978 · Mean difference (final values): -0.2 · 95% CI -1.3 to 1.0
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.5197 · Mean difference (final values): -0.4 · 95% CI -1.5 to 0.8
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0751 · Mean difference (final values): -1.1 · 95% CI -2.2 to 0.1
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.1079 · Mean difference (final values): -1.0 · 95% CI -2.1 to 0.2
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0065 · Mean difference (final values): -1.6 · 95% CI -2.8 to -0.5
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.2529 · Mean difference (final values): 0.7 · 95% CI -0.5 to 1.8
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.6364 · Mean difference (final values): -0.3 · 95% CI -1.3 to 0.8
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9417 · Mean difference (final values): 0.0 · 95% CI -1.1 to 1.0
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0200 · Mean difference (final values): -1.3 · 95% CI -2.3 to -0.2
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0527 · Mean difference (final values): -1.1 · 95% CI -2.1 to 0.0
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.0107 · Mean difference (final values): -1.4 · 95% CI -2.5 to -0.3
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0303 · Mean difference (final values): -1.2 · 95% CI -2.2 to -0.1
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.6889 · Mean difference (final values): -0.2 · 95% CI -1.3 to 0.8
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.9552 · Mean difference (final values): 0.0 · 95% CI -1.2 to 1.1
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.7558 · Mean difference (final values): 0.2 · 95% CI -1.0 to 1.3
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.1824 · Mean difference (final values): -0.8 · 95% CI -1.9 to 0.4
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.3323 · Mean difference (final values): -0.6 · 95% CI -1.7 to 0.6
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.0413 · Mean difference (final values): -1.2 · 95% CI -2.4 to 0.0
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0925 · Mean difference (final values): -1.0 · 95% CI -2.2 to 0.2
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.7133 · Mean difference (final values): -0.2 · 95% CI -1.4 to 0.9
SecondaryPsychomotor Vigilance Task (PVT) Scores

PVT assesses behavioral alertness. Subjects were required to respond to a visual stimulus by pressing a button on a mechanical device and the reaction time was measured. Higher scores indicate attention lapses.

Time frame:
Over a period of 12 hours
Reported as:
Least squares mean · msec
Psychomotor Vigilance Task (PVT) Scores
msecSPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlacebo
Psychomotor Vigilance Task (PVT) Scores243.6 ± 3.59234.8 ± 3.58243.5 ± 3.58243.7 ± 3.59270.2 ± 3.59
Statistical analysis
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -26.5 · 95% CI -36.6 to -16.5
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -35.4 · 95% CI -45.5 to -25.4
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -26.7 · 95% CI -36.7 to -16.6
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -26.5 · 95% CI -36.6 to -16.5
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9945 · Mean difference (final values): 0.0 · 95% CI -10.1 to 10.0
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0814 · Mean difference (final values): -8.9 · 95% CI -18.9 to 1.1
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9743 · Mean difference (final values): -0.2 · 95% CI -10.2 to 9.9
SecondaryPVT Scores by Timepoint

PVT assesses behavioral alertness. Subjects were required to respond to a visual stimulus by pressing a button on a mechanical device and the reaction time was measured. Higher scores indicate attention lapses.

Time frame:
Over a period of 12 hours
Reported as:
Least squares mean · msec
PVT Scores by Timepoint
msecSPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlacebo
9:15pm231.6 ± 3.50233.2 ± 3.49234.9 ± 3.49235.5 ± 3.49241.3 ± 3.50
11:15pm232.6 ± 2.98230.9 ± 2.97231.2 ± 2.97229.3 ± 2.97249.3 ± 2.98
1:15am231.5 ± 3.89231.5 ± 3.88230.2 ± 3.89233.0 ± 3.88256.7 ± 3.89
3:15am243.6 ± 4.65227.4 ± 4.64240.7 ± 4.64242.5 ± 4.64280.7 ± 4.65
5:15am253.4 ± 4.67237.7 ± 4.66242.5 ± 4.66249.5 ± 4.66291.6 ± 4.67
7:15am257.9 ± 7.67242.6 ± 7.67259.2 ± 7.67259.1 ± 7.67295.5 ± 7.67
9:15am254.8 ± 10.84240.0 ± 10.84265.9 ± 10.84256.7 ± 10.93276.1 ± 10.84
Statistical analysis
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.0544 · Mean difference (final values): -9.6 · 95% CI -19.4 to 0.2
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.4410 · Mean difference (final values): -3.8 · 95% CI -13.6 to 6.0
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.1046 · Mean difference (final values): -8.1 · 95% CI -17.9 to 1.7
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.6467 · Mean difference (final values): -2.3 · 95% CI -12.0 to 7.5
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.1971 · Mean difference (final values): -6.4 · 95% CI -16.2 to 3.4
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9052 · Mean difference (final values): -0.6 · 95% CI -10.4 to 9.2
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.2420 · Mean difference (final values): -5.8 · 95% CI -15.6 to 4.0
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): -16.7 · 95% CI -25.1 to -8.3
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.4321 · Mean difference (final values): 3.3 · 95% CI -5.0 to 11.6
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -18.4 · 95% CI -26.7 to -10.1
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.6999 · Mean difference (final values): 1.6 · 95% CI -6.7 to 9.9
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -18.1 · 95% CI -26.4 to -9.8
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.6566 · Mean difference (final values): 1.9 · 95% CI -6.4 to 10.2
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -20.0 · 95% CI -28.3 to -11.7
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -25.2 · 95% CI -36.1 to -14.3
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.7824 · Mean difference (final values): -1.5 · 95% CI -12.4 to 9.4
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -25.1 · 95% CI -36.0 to -14.3
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.7867 · Mean difference (final values): -1.5 · 95% CI -12.4 to 9.4
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -26.5 · 95% CI -37.4 to -15.6
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.6029 · Mean difference (final values): -2.9 · 95% CI -13.7 to 8.0
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -23.6 · 95% CI -34.5 to -12.8
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -37.1 · 95% CI -50.1 to -24.1
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.8684 · Mean difference (final values): 1.1 · 95% CI -11.9 to 14.1
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -53.3 · 95% CI -66.3 to -40.3
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0228 · Mean difference (final values): -15.1 · 95% CI -28.1 to -2.1
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -40.0 · 95% CI -53.0 to -27.0
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.7852 · Mean difference (final values): -1.8 · 95% CI -14.8 to 11.2
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -38.2 · 95% CI -51.2 to -25.2
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -38.2 · 95% CI -51.3 to -25.1
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.5528 · Mean difference (final values): 3.9 · 95% CI -9.1 to 17.0
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -53.9 · 95% CI -67.0 to -40.9
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.0747 · Mean difference (final values): -11.8 · 95% CI -24.9 to 1.2
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -49.2 · 95% CI -62.2 to -36.1
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.2868 · Mean difference (final values): -7.1 · 95% CI -20.1 to 6.0
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -42.1 · 95% CI -55.2 to -29.1
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.0007 · Mean difference (final values): -37.6 · 95% CI -59.1 to -16.2
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9089 · Mean difference (final values): -1.2 · 95% CI -22.7 to 20.2
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -52.9 · 95% CI -74.3 to -31.4
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.1307 · Mean difference (final values): -16.5 · 95% CI -37.9 to 5.0
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.0011 · Mean difference (final values): -36.3 · 95% CI -57.7 to -14.8
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.9903 · Mean difference (final values): 0.1 · 95% CI -21.3 to 21.6
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.0010 · Mean difference (final values): -36.4 · 95% CI -57.8 to -14.9
  • SPD489 20 mg vs Placebo · Mixed Models Analysis · p = 0.1655 · Mean difference (final values): -21.4 · 95% CI -51.7 to 9.0
  • SPD489 20 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.8975 · Mean difference (final values): -2.0 · 95% CI -32.4 to 28.5
  • SPD489 50 mg vs Placebo · Mixed Models Analysis · p = 0.0199 · Mean difference (final values): -36.2 · 95% CI -66.5 to -5.8
  • SPD489 50 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.2785 · Mean difference (final values): -16.8 · 95% CI -47.2 to 13.7
  • SPD489 70 mg vs Placebo · Mixed Models Analysis · p = 0.5048 · Mean difference (final values): -10.3 · 95% CI -40.6 to 20.1
  • SPD489 70 mg vs Armodafinil 250 mg · Mixed Models Analysis · p = 0.5533 · Mean difference (final values): 9.1 · 95% CI -21.3 to 39.6
  • Armodafinil 250 mg vs Placebo · Mixed Models Analysis · p = 0.2098 · Mean difference (final values): -19.4 · 95% CI -49.9 to 11.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489 20 mg—0/27 (0%)1/27 (3.7%)
SPD489 50 mg—0/27 (0%)5/27 (18.5%)
SPD489 70 mg—0/27 (0%)4/27 (14.8%)
Armodafinil 250 mg—0/27 (0%)3/27 (11.1%)
Placebo—0/27 (0%)1/27 (3.7%)
Most frequent other events
Most frequent other events
EventSPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlacebo
HeadacheNervous system disorders0/274/272/272/271/27
NauseaGastrointestinal disorders1/271/272/271/270/27
VomitingGastrointestinal disorders0/272/270/270/270/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)SPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlaceboTotal
Mean26.4 ± 5.0328.7 ± 5.9528.3 ± 5.0427.0 ± 5.0928.1 ± 6.8327.7 ± 5.62
Age, Customized
Age, Customized(Participants)SPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlaceboTotal
18 to 40 years2727272727135
Sex: Female, Male
Sex: Female, Male(Participants)SPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlaceboTotal
Female000000
Male2727272727135
Region of Enrollment
Region of Enrollment(Participants)SPD489 20 mgSPD489 50 mgSPD489 70 mgArmodafinil 250 mgPlaceboTotal
United States2727272727135
08

Study locations

1 site
  • Clinilabs, Inc.
    New York, New York 10019, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2010 to primary completion in Jul 2010, 3 months.

Results were first posted in Jun 2011, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2010
First posted
Mar 31, 2010
StartActual
Apr 5, 2010
Primary completionActual
Jul 18, 2010
CompletionActual
Jul 18, 2010
Results first posted
Jun 23, 2011
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01096680
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Mar 31, 2010
Start date
Apr 5, 2010
Primary completion
Jul 18, 2010
Completion
Jul 18, 2010
Results posted
Jun 23, 2011
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion